Timestamps:

4:50 - Developing brain computer interfaces

10:54 - What is diabetic neuropathy?

16:00 - Dealing with a huge market size

17:50 - The challenges of medtech regulation

19:43 - How patent strategy can make or break you

This episode was co-produced by the ⁠⁠Female Founders Initiative⁠⁠.

About Greta Preatoni:

Greta Preatoni is the co-founder and CEO of Mynerva, a startup developing a groundbreaking device for the treatment of neuropathy. She holds a PhD in Neuroengineering from ETH and started Mynerva in 2023, as soon as she finished her studies.

Neuropathy in general is a condition which causes both loss of sensation in the nerves and, paradoxically, chronic pain. It can be caused by diabetes, chemotherapy and even by COVID. Most of Mynerva’s patients are diabetics, who before accessing their solution were forced to rely on opioids with severe side effects. Despite relieving pain, the drugs also increased the likelihood of falls (from lack of sensation in the patient’s foot soles).

The Mynerva team created Leia, a peerless non-invasive device with a sensorized insole that captures the information from the foot-ground interaction and translates it into electrical impulses delivered on the skin. The optimally designed electrode placement and shape, together with AI-based algorithms, are able to directly target the nerves and reduce neuropathic pain. All health-related parameters are collected by the sensorized insole and a wearable bracelet to drive data-driven individualized therapies.

At present, Mynerva is actively focusing on obtaining the necessary certifications for their medical device.

FreshEd #399 – EdTech Philanthropy in South Africa (Amy Stambach)